null
US
Iniciar Sesión
Regístrate Gratis
Registro
Hemos detectado que no tienes habilitado Javascript en tu navegador. La naturaleza dinámica de nuestro sitio requiere que Javascript esté habilitado para un funcionamiento adecuado. Por favor lee nuestros
términos y condiciones
para más información.
Siguiente
Copiar y Editar
¡Debes iniciar sesión para completar esta acción!
Regístrate gratis
53844
Treatment of human african trypanosomiasis (HAT)
Descripción
Microbiology Mapa Mental sobre Treatment of human african trypanosomiasis (HAT), creado por maisie_oj el 22/04/2013.
Sin etiquetas
microbiology
microbiology
Mapa Mental por
maisie_oj
, actualizado hace más de 1 año
Más
Menos
Creado por
maisie_oj
hace más de 11 años
120
0
0
Resumen del Recurso
Treatment of human african trypanosomiasis (HAT)
Three considerations for HAT therapy
1) what stage to target?
Stage; bloodstream (dividing trypomastigotes) or CNS 'dormant' parasites
Major clical manifestations often present during the CNS phase - stage to target?
2) blood brain barrier
Defines physico-chemical properties of the drug (e.g. Polar etc.)
3) sub species
Difference in drug sensitivity of T. b. gambiense (W african) and T. b. rhodesiense (E african)
Current drugs against early stage HAT
SURAMIN (trade name = germanin)
Introduced in 1922 (by Bayer - phamaceutical company)
Drug of chce against early stage E African trypanosomiasis (T.b. rhodesiense)
Not used for W African (T.b. gambiense) - instead it is reserved for river blindness (caused by Onchocerca volvulus)
Absorption/dose
Weekly 1g (IV), for 5-6 weeks [$10/g]
Structure
Symmetrical
Based on a core molecule of urea (CO(NH2)2)
Features two naphthylamine (x2 six carbon rings with an NH2 sidechain)
Polysulfonated (features six sulfonate groups)
Make drug negatively charged at physlogical pH
Important for function! - negative charge allows for interaction with parasite proteins
Distribution
99% is protein bound due to negative charge
Passes poorly through BBB due to negative charge
Elimination
Not metabolised (long half life) - approx. 35-60 days
Side effects
Albminuria (protein in urine) - stops after end of treatment course
Mode of action (MOA)
Uptake
Suramin binds to the parasite receptor ISG7S (invariant surface glycoprotein 7S)
Receptor moves theough he fluid mosaic membrane and ends up in the flagellal pit - here the suramin bound ISG7S is ubiquitinated
This receptor modification (Ub) recruits adaptins to the inner surface of the membrane
Adaptins recruit a clathrin coat to form beneath the surface of the membrane around the receptor-suramin complex
Clathrin coated pit forms and the receptor-surmain complex enters the cell through receptor-mediated endocytosis (forms clathrin-coated vesicle)
In cytoplasm: clathrin disassociates from the vesicle, the uncoated vesicle then fuses with an endosome then a lysosome
In lysosome: proteases (serine peptidase [CSB] and cysteine protease [CatL]) act on the receptor, causing suramin to disassociate from ISG7S
The acidic lysosome causes suramin to loose its charge - it then passes through the major facilitator superfamily transporter (MFST) to the cytoplasm
In cytoplasm: the MOA od suramin still unclear - preseumed effects;
Inhibition of endocytotic enzymes (3'-nucleotidase, protein kinase, acid phosphatase, acid pyrophosphatase, phospholipase A1)
Ihibition of glycolytic enzymes (affecting glycolysis - demonstrated in test tube)
Inhibits polyamine synthesis
Inhibits N-acetly glucasamine (important part of the VSG glycosylphosphatidylinsositol (GPI) anchor - immune evasion
ISG7S is receylced
So far there have been no reports of resistence to suramin
Probably due to its numerous effects
Pentamidine (PMD)
Structure
Symmetrical
Two aromatic terminals which feature an amidine group (R(=NH)NH2) - making the molecule a diamidine
Positively charged at physlogical pH
Introduced in 1937
Drug of choice against early stage W. African trypanosomiasis (T.b. gambiense)
Also used for resistent leishmaniasis and Pneumocystis carinii pneumonia (PCP)
Absorption/dose
7-10 daily IM injections ($20/course)
Distribution
70% bound to proteins - due to charge
Passes poorly through the BBB (due to charge) - cannot reach therapeutic levels and therefore not used for CNS stage
Elimination
Not metablised - ~15% clearance via urine in 24hrs (half life is abot 9-13hrs)
Side effects
Most people (>90%) have allergic reaction
Stomach upset, loss of apetite, nausea, vomiting, diarrhoea, dizziness and cough
MOA
Uptake is via three membrane transporters
P2 (purine transporter)
Low affinity pentamidine transporter (LAPT)
High affinity pentamidine transporter (HAPT)
Recently proposed as being an aqua-glycero porin (meaning its constanly open)
Possible MAOs in parasite
Binds to mitochondrial DNA - preventing synthesis on new mitochondria (affects splicing)
mtDNA is found within the mitochondira of all eukaryotic cells
Reduces the mitochondrial membranepotential - causing release of ROS and induce apoptosis
Mitochondrial transporter not known
Melarsoprol (MelB)
Structure
Trivaelent, melaminophenyl arsenical (contains arsenic)
Highly toxic - 5-10% of patients die from drug alone
Absorption/dose
Given with adjuvant polyethylene glycol (PEG) and given as IV injection
Very painful! (Arsenic mixed with antifreeze)
Scars blood vessels and causes collapse
Scheme 1: one injection per day for 4days, then a rest period of 7-10days - repeat 3-4 times
Scheme 2: daily injections for 10 days
Both cost $50/course
Introduced in 1949
Only drug available against late stages of both HATs
Distribution
In plasma - can cross BBB (concentration is 50 times lower in the cerebrospinal fluid)
Elimination
Converted to melarsen oxide - rapidly excreted in urine (half life is about 35hrs)
Side effects
Arsenic poisoning (convulsions, fever, loss of conciousness, rashes, bloody stools, nausea and vomiting)
MOA
Uptake into the parasite is via the membrane receptors; P2 and HAPT
MelB is a prodrug -> converted to malarsen oxide (not known whether by the host or parasite)
Melarsn oxide complexes with thiols (any molecule that features reactive cysteine residues)
Protein thiols
Free thiol trypanothione - involved in protection from oxidative stress (effectively two glutathioones)
= two glutathiones (protect against ROS) and a spermadine linker
Complex inhibits trypanothione-dependent enzymes
Trypanothione reductase (TR) which converts trypanothine to dihydrotrypanothne (T(SH)2)
Ribonucleotide reductase (DNA nucleotide synthesis)
Requires trypanothione for redox reaction (electrons taken from thiol groups)
Resistance to melarsoprol
Cells resistant to melarsoprol have a reduced adenine, melarsoprol and melarsen oxide uptake via P2 transporter
Wild type P2 comes from a single copy gene that codes a channel protein with 10 transmembrane domains
In recombinant yeast unable to synthesise purines: expression of parasite P2 allowed yeast to take up adenine, melarsoprol and melarsen oxide
Yeast made sensitive to melarsen oxide
6 point mutations that alter the amino acid sequence of P2 identified - this causes drug resistance
Yeast expressing this mutated P2 did not become sensitive melarsen oxide
In P2 gene knockout experiments
In culture null mutant parasites were more resistant to arsenicals
In animal models, null mutant parasites showed resistance
How does the P2 transport arsenicals?
Due to the structure of the arsenical (e.g. Melarsoprol) - arsenicals share a structural motif similar to adenosine
Feature an aromatic group with a N=C(NH2)
This motif H-bonds with the P2 transporter
The other membrane purine transporter P1 recognises motifs in the ribose sugar ring of the nucleotide which is absent in arsenicals
However, half of drug resitance cases are not due to P2 mutations - therefore other mechanisms of resistance
Potential efflux mechanism proposed - thiol conjugate transporter protein (TbMRPA) was identifiedon the surface of parasites
Melarsoprol binds to thiols
Eliminates conjugated thiols from the cell
Overexpression is associated with resitance, whereas low expression of MRPA is associated with hypersensitivity
Other drugs against CNS (late) stage HAT
Eflornithine (difluoremethylornithine, DFMO)
Structure
Structural analgoue of ornithine (amino acid involved in urea cycle and important for the metabolism of toxic nitrogen)
Fluorinated
Introduced in 1981 (tradename - aventis)
Designed to be an anti-cancer drug
Very few side effects and termed the "miracle" or "resuscitation" drug due to its ability to seemingly revive patients with CNS stage HAT
Absorption/dose
Four daily IV injections (for 1-2weeks, at high dose - 400mg/kg)
$500/course - due to improved production techniques its not about $300
Distribution
In plasma - can cross the BBB (up to 50% of dose in CSF)
Elimination
Not metabolised, rapidly excreted in urine (about 80% in first 24hrs) - half life is 3.5hrs
MOA
Parasite uptake by the amino acid transporter 6 (AAT6)
Down regulation by RNAi of TbAAT6 leads to resistance
Irreversibly binds to onithine decarboxylase (ODC)
Reduces the production rate of polyamines (e.g. Trypanothione) - many knock-on effects
Doesnt directly kill parasite - decreses growth (cytostatic) allowing the immune system to control the infection
Binds to mammalian ODC with same affinity - so how do humans tolerate the drug?
Human ODC turnover is much faster (about 20mins) than trypanosomal ODC turnover (about 4-5hrs in T.b. rhodesiense and 18-19hrs in T.b. gambiense)
In mammals ODC/eflornithine complex is removed and replaced with new ODC faster (barely effecting activity)
In trypanosomes ODC turn around is much slower and there is subsequent loss of ODC activity
Aventis stopped producing eflornithing due to the cost
However vaniqa cream (eflornithine hydrochloride) a treatment for facial hair on women is in production
Market in the Western world
Aventis agreed to donate 5yrs worth of eflornithine to WHO
At a cost of $25M
No market in the Western world
Current drug treatments are problematic
Toxic
Majorly: melarsoprol (melaresn oxide) (based on arsenic - 5-10% of patients die outright)
Minorly: suramin and pentmaidine
Limited efficacy
Suramin only effective against E African trypanosomiasis (T.b. rhodesiense)
Pentamidine only effective against W African trypanosomiasis (T.b. gambiense)
Suramin and pentamidine only effective against non-cerebral forms of HAT
Eflornithine only effective against T.b. gambiense (CNS stage) - T.b. rhodesiense (CNS stage) has a less stable ODC
Resistance
Melarsoprol - mutation of P2 and TbMRPA overexpression
Medical supervision
All!
Expensive
Eflornithine (~$300/course)
Future of HAT treatment
May rely on combinational therapies (i.e. NECT = nifurtimox eflornithin combinatnal therapy)
NECT is used against late stage W African trypanosomiasis (T.b. gambiense)
Alternative for melarsoprol
Cheaper than elfornithine monotherapy (~$150/course)
Mostrar resumen completo
Ocultar resumen completo
¿Quieres crear tus propios
Mapas Mentales
gratis
con GoConqr?
Más información
.
Similar
Chapter 7 - The Blue Print of Life, from DNA to Protein
Dorothy B
Immune System
dsandoval
THE PROTIST MIND MAP
hasvinee
Infection and Disease
hannahcurle
HIV and the immune system
Beth Moore
Protein section 2
MrSujg
Microbiology MCQs 3rd Year Final- PMU
Med Student
Microbiology Test 1 2nd Year PMU
Med Student
Microbiology and Immunology
AchalaM
Horizontal gene transfer
Joe Wanford
Microbiology part 1
Lavinia Hayde
Explorar la Librería